Ashton Holbrook
Family · Charleston, WVNPI 1720430499
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.7% of the total across 567 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 21.6% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in WV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 567 payments — averaging $14.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
- AbbVie$2K
- Ardelyx, Inc.$624
- Takeda Pharmaceuticals U.S.A., Inc.$476
- Sanofi$471
- Johnson & Johnson$469
- plus $3K from 31 others
What the payments were for
- Food & beverage$8,20399%
- Education$1071%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 195 | $1,794 |
| AbbVie | 90 | $1,502 |
| Ardelyx, Inc. | 39 | $624 |
| Takeda Pharmaceuticals U.S.A., Inc. | 35 | $476 |
| Sanofi | 23 | $471 |
| Johnson & Johnson | 21 | $469 |
| Novo Nordisk | 27 | $426 |
| Redhill Biopharma Inc. | 23 | $304 |
| Gilead | 10 | $298 |
| Regeneron Healthcare Solutions, Inc. | 13 | $253 |
| Madrigal Pharmaceuticals | 10 | $223 |
| Bristol Myers Squibb | 12 | $186 |
| Merck | 9 | $165 |
| Pfizer | 7 | $150 |
| Evoke Pharma, Inc. | 6 | $120 |
| Lilly USA, LLC | 6 | $107 |
| Dexcom, Inc. | 5 | $93 |
| QOL Medical, LLC | 3 | $68 |
| Phathom Pharmaceuticals, Inc. | 5 | $65 |
| Exact Sciences | 3 | $59 |
| Celltrion USA Inc. | 2 | $45 |
| Astellas Pharma US Inc | 2 | $40 |
| Nestle Healthcare Nutrition Inc. | 2 | $39 |
| Aimmune Therapeutics, Inc. | 2 | $37 |
| Averitas Pharma Inc. | 2 | $34 |
| Intercept Pharmaceuticals, Inc. | 2 | $31 |
| Medtronic | 1 | $27 |
| Indivior Inc. | 1 | $27 |
| AstraZeneca | 2 | $27 |
| Mallinckrodt Hospital Products Inc. | 2 | $27 |
| Ironwood Pharmaceuticals, Inc | 1 | $24 |
| Daiichi Sankyo Inc. | 1 | $20 |
| Esperion Therapeutics, Inc. | 1 | $19 |
| Fresenius Kabi USA, LLC | 1 | $16 |
| Bayer | 1 | $15 |
| Braintree Laboratories, Inc. | 1 | $14 |
| Boehringer Ingelheim | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Livdelzi$125
How this compares
$8,310 in reported general payments places this provider in the 95th percentile of 1,507 family providers in West Virginia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RezdiffraResmetirom | 34 | $134,339 |
| LinzessLinaclotide | 68 | $67,445 |
| XifaxanRifaximin | 14 | $60,739 |
| IbsrelaTenapanor Hcl | 11 | $22,232 |
| TrulancePlecanatide | 18 | $17,777 |
| MovantikNaloxegol Oxalate | 27 | $12,587 |
| MotegrityPrucalopride Succinate | 12 | $6,626 |
| Sucralfate | 74 | $2,658 |
| Colestipol Hcl | 27 | $2,373 |
| Famotidine | 226 | $2,326 |
| Pantoprazole Sodium | 253 | $2,016 |
| Dicyclomine Hcl | 116 | $1,622 |
| Ondansetron OdtOndansetron | 59 | $969 |
| Mesalamine | 12 | $528 |
| Omeprazole | 59 | $480 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Madrigal PharmaceuticalsRezdiffra | $223 | $134,33934 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance | $1,794 | $78,51632 claims |
| AbbVieLinzess | $1,502 | $67,44568 claims |
| Ardelyx, Inc.Ibsrela | $624 | $22,23211 claims |
| Redhill Biopharma Inc.Movantik | $304 | $12,58727 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $476 | $6,62612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,507 family providers in West Virginia.
Other family in Charleston
- Ashley ComerCharleston$213K
- Sarah KnightCharleston$99K
- Angela SettleCharleston$51K
- Malea SmithCharleston$13K
- Michelle MurrayCharleston$13K
- Kara DravenstottCharleston$11K
- Stacy RichardsonCharleston$11K
- Rebecca ButcherCharleston$9K
- Jade LewisCharleston$8K
- Samantha StoneCharleston$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.